⇚ Regimen KEYTRUDA® - for Malignant Melanoma Medical Name KEYTRUDA® (Pembrolizumab) - for advanced Malignant Melanoma Cycles Given 4 Delivery Phases N/A Special Instructions Monitor closely for immune mediated end organ damage such as Pneumonitis, Colitis, Hepatitis and Nephritis. Continue KEYTRUDA® until disease progression or unacceptable toxicity. References Ribas A, et al. 2014 ASCO Meeting - VIEW External References http://meetinglibrary.asco.org/print/1738605 - VIEW Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration KEYTRUDA® (Pembrolizumab) IV 2 mg/kg D1 q21 NSS 250 cc 60 minutes